Process development and pilot batches
The supplier works out how to make the peptide reliably, then makes small pilot batches. Material from this stage is labeled for research and development use only, not for human use.
PEPTIDE SOURCING · 503A EDUCATION
How to vet a peptide API supplier
before a program depends on it.
The new HHS peptide policy puts ingredient sourcing first. Here is what it takes a supplier to qualify a peptide active pharmaceutical ingredient (API), why an offer made days after the policy deserves questions, and what to ask before you rely on one.
PCAB accredited · licensed in all 50 states + DC
Certificates checked before acceptancecGMP-compliant suppliersLicensed in all 50 states + DCPCAB accredited
WHAT CHANGED
The policy opened a path.
Sourcing is the first gate.
On October 29, 2026, HHS released an interim enforcement discretion policy for six peptides. It describes conditions under which a 503A pharmacy may compound them for individual patients while a decision on the 503A bulks list is pending. Those conditions start with the ingredient: qualified API sourcing, testing and certificates of analysis, and reporting of serious adverse events and product-quality issues.
The federal policy is only one layer. State boards of pharmacy decide how it fits their own rules, and they are expected to differ. Reporting systems for 503A pharmacies are still being worked out. For any clinic or telehealth program, that makes the ingredient supplier the first question rather than the last.
In recent conversations with API suppliers, our pharmacists have heard the same thing: qualifying a peptide API takes a long sequence of development, GMP batches, studies and documentation. Some suppliers have already finished the research-use-only phase, and some steps can run side by side. But a supplier claiming to meet the new conditions, or offering to sell these peptides, days after the guidance was released deserves careful questions.
“I am not skeptical of peptides. I am skeptical of hype.”Jessica Patrone, Pharm.D., President, CEO & Owner, ProCompounding
THE PATH TO API GRADE
What a supplier has to do before a peptide API is qualified.
This is the general sequence API suppliers describe for taking a peptide from development to API grade. Until the end of it, batches are labeled for research and development use only.
Analytical methods, developed and validated
Before anyone can say a batch is what it claims to be, the supplier needs validated methods to test its starting materials and its product for identity, purity and strength.
A GMP engineering batch
A larger batch is made under current good manufacturing practice, and the testing methods are validated again for that batch. It is still research-use-only material.
Impurities study and a reference standard
The supplier characterizes the impurities its process creates and builds a reference standard to measure against. The impurities study alone can run for more than a year.
Risk assessment and qualification batches
A formal risk assessment, then three process qualification batches made under GMP to show the process repeats. These batches are still labeled for research and development use only.
Stability data and the paperwork
A stability study across the engineering and qualification batches runs for years. A drug master file, a cleaning validation report and validation documents complete the path to API grade.
How we source every ingredient: every active pharmaceutical ingredient we use comes from an FDA-registered, cGMP-compliant supplier, and we check the certificate of analysis for identity, potency and purity before a raw material is accepted into inventory. Read more about compounding quality and sourcing.
RED FLAGS
Three signs an offer needs a closer look.
“Ready now”, days after the policy
The policy is new. The path to a qualified peptide API is long, and some of it cannot be hurried. A supplier that says it already meets the new conditions should be able to show every step, with documents.
A certificate with no traceable source
A certificate of analysis is only as reliable as the source behind it. Pharmacy regulators have reported falsified certificates and expect more as new suppliers arrive. Confirm the ingredient came from the manufacturer named on the certificate.
Research-use-only material
Batches made during development are labeled for research and development use only, not for human use. An attractive offer does not change what the label says. See how we manage quality.
TALK WITH OUR TEAM
Planning a program?
Start with the ingredients.
Tell us what your program prescribes. Our pharmacists will walk you through how we qualify ingredients, what 503A rules require, and how licensure works in the states where your patients live.
- How we check a certificate of analysis before an ingredient is accepted
- What 503A rules mean for your formulary
- Schedule a visit to our Johnson City lab
Already ready to set up your clinic?Start in the Clinic Onboarding app
THE CHECKLIST
Seven questions to ask
any peptide API supplier.
Ask for documents, not reassurance. For the regulatory background, see what a 503A pharmacy is and how PCAB accreditation reviews a pharmacy’s practices.
- 01
Who manufactured this API, and can you document every step from that manufacturer to us?
- 02
Was this lot made under GMP, and has the process been through qualification batches?
- 03
Does the certificate of analysis come from the manufacturer, and how can we verify it independently?
- 04
What impurities testing has been done, and against which reference standard?
- 05
What stability data supports this material?
- 06
Is there a drug master file or equivalent documentation we can reference?
- 07
Is any of this material labeled for research use only?
FREQUENTLY ASKED QUESTIONS
The policy,
in plain words.
What is the HHS peptide enforcement discretion policy?
On October 29, 2026, the U.S. Department of Health and Human Services released an interim policy for six peptides (BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500) that a federal pharmacy compounding advisory committee reviewed in July. It sets conditions under which 503A pharmacies may compound them for individual patients while a decision on the 503A bulks list is pending. The conditions include qualified ingredient sourcing, testing and certificates of analysis, and reporting of serious adverse events and product-quality issues.
Does the HHS policy override state pharmacy rules?
No. State boards of pharmacy are not required to follow the federal policy, and they are expected to take a range of approaches. Some states have already restricted certain peptides, and others have moved the other way. Any program has to account for the rules in every state where its patients live.
What does “research use only” mean on a peptide ingredient?
It means the material is intended for research and development, not for use in people. Peptide batches made while a supplier is still developing and qualifying its process carry that label until the process reaches API grade.
How long does it take a supplier to qualify a peptide API?
There is no single answer, and some steps can run in parallel. The path includes process development, validated testing methods, GMP batches, an impurities study that can run for more than a year and a stability study that runs for years, followed by a drug master file and validation documents. That is why a claim of full readiness so soon after the policy deserves questions.
Is a certificate of analysis enough to trust a peptide ingredient?
A certificate of analysis records test results, but it is only as reliable as the source behind it. Pharmacy regulators have reported falsified certificates. Check that the ingredient came from the manufacturer named on the certificate and that the results can be verified.
Who reports adverse events under the new policy?
The policy asks compounders to report serious adverse events and product-quality issues to federal and state regulators. How those reports are made, on what timeline and in what format is still being worked out, and pharmacy regulators have asked for more detail.
This page is for education about ingredient sourcing and regulation. It is not legal or medical advice and is not an offer of any product. Compounded preparations are not reviewed or approved by the FDA for safety or efficacy.